Unknown

Dataset Information

0

Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.


ABSTRACT:

Background

Tumour expression of selected microRNAs (miRs) correlates with cisplatin efficacy in multiple cancers. We investigated the role of selected miRs in patients receiving cisplatin-based therapy for advanced urothelial carcinoma (UC).

Methods

RNA was extracted from formalin-fixed paraffin-embedded tumour from 83 advanced UC patients who received cisplatin. A miR panel based on relevance for platinum sensitivity and UC was studied by quantitative reverse transcription quantitative PCR (RT-qPCR). Association of progression-free survival (PFS) with miR expression was analysed using cox regression. Selected TFs were chosen by association with the panel of miRs using the Transcription Regulation algorithm (GeneGo MetaCore+MetaDrug version 6.23 build 67496). Bladder cancer (BC) cell lines were used to investigate the previously described role of miR-21 mediating cisplatin sensitivity.

Results

The 83 patients had a median PFS of 8 months. In multivariate analysis, higher levels of E2F1 (P=0.01, HR: 1.95 (1.14, 3.33)), miR-21 (P=0.01, HR: 2.01 (1.17, 3.45)) and miR-372 (P=0.05, HR: 1.70 (1.00, 2.89)) were associated with a shorter PFS. In the 8 BC cell lines, miR-21 was not shown to be necessary nor sufficient for modulating cisplatin sensitivity.

Conclusions

In metastatic UC patients treated with cisplatin-based therapy, high primary tumour levels of E2F1, miR-21 and miR-372 are associated with poor PFS independent of clinical prognostic factors. The in vitro study could not confirm miR-21 levels role in modulating platinum sensitivity.

SUBMITTER: Bellmunt J 

PROVIDER: S-EPMC4931368 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.

Bellmunt Joaquim J   Zhou Chensheng Willa CW   Mullane Stephanie A SA   Werner Lillian L   Taplin Mary-Ellen ME   Fay André P AP   Choueiri Toni K TK   Orsola Anna A   Takeda David Y DY   Hahn William C WC   Kim Jaegil J   Sonpavde Guru G   Bowden Michaela M  

British journal of cancer 20160623 1


<h4>Background</h4>Tumour expression of selected microRNAs (miRs) correlates with cisplatin efficacy in multiple cancers. We investigated the role of selected miRs in patients receiving cisplatin-based therapy for advanced urothelial carcinoma (UC).<h4>Methods</h4>RNA was extracted from formalin-fixed paraffin-embedded tumour from 83 advanced UC patients who received cisplatin. A miR panel based on relevance for platinum sensitivity and UC was studied by quantitative reverse transcription quanti  ...[more]

Similar Datasets

| S-EPMC6814293 | biostudies-literature
| S-EPMC6827133 | biostudies-literature
| S-EPMC5576985 | biostudies-literature
| S-EPMC9441572 | biostudies-literature
| S-EPMC10632822 | biostudies-literature
| S-EPMC3708886 | biostudies-literature
| S-EPMC2361525 | biostudies-other
| S-EPMC9205436 | biostudies-literature
| S-EPMC6299080 | biostudies-literature
| S-EPMC9529860 | biostudies-literature